UPDATED Feb 14, 2024
Defensive mid-caps and large-caps in descending order of expected ROE in three years.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
300009Anhui Anke Biotechnology (Group) | CN¥10.01 | 0% | -10.5% | CN¥16.7b | CN¥19.54 | PE21.9x | E21.9% | 2.5% | ||
739Apeloa PharmaceuticalLtd | CN¥13.50 | 0% | -41.3% | CN¥15.8b | CN¥23.46 | PE13.3x | E20.9% | 2.2% | ||
600750Jiang Zhong PharmaceuticalLtd | CN¥22.77 | 0% | 44.5% | CN¥14.2b | CN¥30.00 | PE20.8x | E14.3% | 5.5% | ||
600566Hubei Jumpcan Pharmaceutical | CN¥34.27 | 0% | 14.3% | CN¥31.6b | CN¥42.71 | PE12.5x | E10.0% | 2.6% | ||
2603Shijiazhuang Yiling Pharmaceutical | CN¥20.75 | 0% | -32.5% | CN¥34.7b | CN¥27.02 | PE12.8x | E7.9% | 2.4% | ||
513Livzon Pharmaceutical Group | CN¥36.98 | 0% | 7.8% | CN¥29.8b | CN¥39.75 | PE17x | E8.8% | 4.3% | ||
2422Sichuan Kelun Pharmaceutical | CN¥26.17 | 0% | -9.4% | CN¥39.1b | CN¥38.83 | PE17.2x | E12.1% | 2.4% | ||
600062China Resources Double-Crane PharmaceuticalLtd | CN¥18.99 | 0% | 3.7% | CN¥19.7b | CN¥26.00 | PE15.6x | E18.2% | 3.0% | ||
600535Tasly Pharmaceutical Group | CN¥15.89 | 0% | 28.4% | CN¥23.7b | CN¥14.92 | PE21.2x | E10.6% | 2.1% |